We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

TNF-α

Tumor necrosis factor alpha (TNF-α) inhibitors reduce the production or signaling of a central inflammatory cytokine. In 1975 an endotoxin-induced serum factor that causes necrosis of tumors was described and named tumor necrosis factor. Cloning of human TNF in 1984 revealed a precursor related to lymphotoxin. Through its two receptors, TNF-α activates nuclear factor kappa B (NF-κB) and cell death pathways. Etanercept is a soluble receptor fusion protein that binds the cytokine, and C 87 is a small-molecule TNF-α inhibitor. In 1991 thalidomide was shown to inhibit TNF-α production by stimulated human monocytes, and its analogs lenalidomide and pomalidomide are also listed. Pathway compounds include the NF-κB inhibitor QNZ and necrostatin-1, an inhibitor of receptor-interacting protein kinase 1 (RIPK1).

1 Item

  • IDT
    Cat. No.
    A25512
    CAS No.
    18138-19-7

    IDT

    IDT is a TNFα modulator that targets and regulates the innate immune response. It has demonstrated significant efficacy in reducing paired helical filament tau and fibrillar amyloid accumulation, as well as enhancing the infiltration of neutrophils while decreasing TNFα expression within this population. IDT is a valuable reagent for research focused on Alzheimer’s disease and the underlying mechanisms of neuroinflammation.

    In stock View Details
    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...